News articles about Kite Pharma (NASDAQ:KITE) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kite Pharma earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.084848544629 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Kite Pharma (NASDAQ KITE) remained flat at $$179.79 during midday trading on Friday. Kite Pharma has a 1 year low of $39.82 and a 1 year high of $179.95. The firm has a market cap of $10,280.00 and a price-to-earnings ratio of -26.06.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Kite Pharma (KITE) Share Price” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/01/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-kite-pharma-kite-share-price.html.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Stock Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related stocks with our FREE daily email newsletter.